Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action
Rafael G. dos Santos, Jaime EC Hallak, Glen B. Baker, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 453-458
Closed Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Lily R. Aleksandrova, Anthony G. Phillips
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 11, pp. 929-942
Closed Access | Times Cited: 171
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder
Joshua D. Rosenblat, M. Ishrat Husain, Yena Lee, et al.
The Canadian Journal of Psychiatry (2022) Vol. 68, Iss. 1, pp. 5-21
Open Access | Times Cited: 43
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020
Emma I Kopra, Jason Ferris, Adam Winstock, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 7, pp. 733-748
Open Access | Times Cited: 37
Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
M. Ishrat Husain, Nicole Ledwos, Elise Fellows, et al.
Frontiers in Psychiatry (2023) Vol. 13
Open Access | Times Cited: 31
Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity
James E. Glazer, Conor H. Murray, Robin Nusslock, et al.
Neuropsychopharmacology (2022) Vol. 48, Iss. 2, pp. 418-426
Closed Access | Times Cited: 36
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans
Paul Cumming, Milan Scheidegger, Dario A. Dornbierer, et al.
Molecules (2021) Vol. 26, Iss. 9, pp. 2451-2451
Open Access | Times Cited: 37
Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review
Dominika Psiuk, Emilia Nowak, Natalia Dycha, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11450-11450
Open Access | Times Cited: 27
Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis
Chia‐Ling Yu, Chih‐Sung Liang, Fu‐Chi Yang, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 4, pp. 938-938
Open Access | Times Cited: 26
Overview of treatment-resistant depression
Cheng‐Ta Li
Progress in brain research (2023), pp. 1-23
Closed Access | Times Cited: 15
Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity
Débora Copa, David Erritzøe, Bruna Giribaldi, et al.
Journal of Affective Disorders (2024) Vol. 353, pp. 60-69
Closed Access | Times Cited: 5
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Blerida Banushi, Vince Polito
Biology (2023) Vol. 12, Iss. 11, pp. 1380-1380
Open Access | Times Cited: 13
The novel non-hallucinogenic compound DM506 (3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole) induces sedative- and anxiolytic-like activity in mice by a mechanism involving 5-HT2A receptor activation
Hugo R. Arias, Deborah Rudin, Dustin J. Hines, et al.
European Journal of Pharmacology (2024) Vol. 966, pp. 176329-176329
Open Access | Times Cited: 4
Exploring Psychedelics for Unmet Needs in Women’s Reproductive Health
Sara Shoar, Alissa Bazinet, Chaitra Jairaj
Psychedelic Medicine (2025)
Closed Access
A qualitative analysis of the psychedelic mushroom come-up and come-down
Ari Brouwer, Joshua K. Brown, Earth Erowid, et al.
npj Mental Health Research (2025) Vol. 4, Iss. 1
Open Access
Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives
Sung‐Hyun Kim, Sumin Yang, Jeehye Jung, et al.
Advanced Science (2025)
Open Access
Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs
Nicholas C. Borgogna, Tyler Owen, Dan Petrovitch, et al.
Psychopharmacology (2025)
Open Access
A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life
Sarah Kratina, Carol Strike, Robert D. Schwartz, et al.
PLoS ONE (2025) Vol. 20, Iss. 5, pp. e0318343-e0318343
Open Access
Role of Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors and Psychedelics in the Treatment of Major Depressive Disorder: A Perspective on Mechanistic Insight and Current Status
Niharika Singh, Puja Panwar Hazari, Parul Mittal, et al.
European Journal of Pharmacology (2025), pp. 177737-177737
Closed Access
Serotonergic Psychedelics in Neural Plasticity
Kacper Łukasiewicz, Jacob J. Baker, Yi Zuo, et al.
Frontiers in Molecular Neuroscience (2021) Vol. 14
Open Access | Times Cited: 22
A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants
Nicole Ledwos, Joshua D. Rosenblat, Daniel M. Blumberger, et al.
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 6, pp. 581-588
Closed Access | Times Cited: 12
Cannabis-assisted psychotherapy for complex dissociative posttraumatic stress disorder: A case report
Anya Ragnhildstveit, Miriam Kaiyo, Matthew Brian Snyder, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 7
DM506 (3-Methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole fumarate), a Novel Derivative of Ibogamine, Inhibits α7 and α9α10 Nicotinic Acetylcholine Receptors by Different Allosteric Mechanisms
Han‐Shen Tae, Marcelo O. Ortells, Bassel Tekarli, et al.
ACS Chemical Neuroscience (2023) Vol. 14, Iss. 14, pp. 2537-2547
Closed Access | Times Cited: 7
Perspectives and preliminary experiences of psychedelics for the treatment of eating disorders: A systematic scoping review
Karolina Cuerva, Dean Spirou, A. García Cuerva, et al.
European Eating Disorders Review (2024) Vol. 32, Iss. 5, pp. 980-1001
Open Access | Times Cited: 2
Adverse Effects After Ayahuasca Administration in the Clinical Setting
Juliana Mendes Rocha, Giordano Novak Rossi, Flávia de Lima Osório, et al.
Journal of Clinical Psychopharmacology (2022) Vol. 42, Iss. 3, pp. 321-324
Closed Access | Times Cited: 10
The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials
Giordano Novak Rossi, Jaime E. C. Hallak, Glen B. Baker, et al.
European Archives of Psychiatry and Clinical Neuroscience (2022) Vol. 273, Iss. 1, pp. 129-155
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top